Your browser doesn't support javascript.
loading
Phenotypic variability to medication management: an update on fragile X syndrome.
Elhawary, Nasser A; AlJahdali, Imad A; Abumansour, Iman S; Azher, Zohor A; Falemban, Alaa H; Madani, Wefaq M; Alosaimi, Wafaa; Alghamdi, Ghydda; Sindi, Ikhlas A.
Afiliação
  • Elhawary NA; Department of Medical Genetics, College of Medicine, Umm Al-Qura University, Mecca, 21955, Saudi Arabia. naelhawary@uqu.edu.sa.
  • AlJahdali IA; Department of Community Medicine, College of Medicine, Umm Al-Qura University, Mecca, Saudi Arabia.
  • Abumansour IS; Department of Medical Genetics, College of Medicine, Umm Al-Qura University, Mecca, 21955, Saudi Arabia.
  • Azher ZA; Department of Medical Genetics, College of Medicine, Umm Al-Qura University, Mecca, 21955, Saudi Arabia.
  • Falemban AH; Department of Pharmacology and Toxicology, College of Medicine, Umm Al-Qura University, Mecca, 24382, Saudi Arabia.
  • Madani WM; Department of Hematology and Immunology, Faculty of Medicine, Umm Al-Qura University, Mecca, Saudi Arabia.
  • Alosaimi W; Department of Hematology, Maternity and Children Hospital, Mecca, Saudi Arabia.
  • Alghamdi G; Department of Medical Genetics, College of Medicine, Umm Al-Qura University, Mecca, 21955, Saudi Arabia.
  • Sindi IA; Department of Biology, Faculty of Science, King Abdulaziz University, Jeddah, 21589, Saudi Arabia.
Hum Genomics ; 17(1): 60, 2023 Jul 07.
Article em En | MEDLINE | ID: mdl-37420260
ABSTRACT
This review discusses the discovery, epidemiology, pathophysiology, genetic etiology, molecular diagnosis, and medication-based management of fragile X syndrome (FXS). It also highlights the syndrome's variable expressivity and common comorbid and overlapping conditions. FXS is an X-linked dominant disorder associated with a wide spectrum of clinical features, including but not limited to intellectual disability, autism spectrum disorder, language deficits, macroorchidism, seizures, and anxiety. Its prevalence in the general population is approximately 1 in 5000-7000 men and 1 in 4000-6000 women worldwide. FXS is associated with the fragile X messenger ribonucleoprotein 1 (FMR1) gene located at locus Xq27.3 and encodes the fragile X messenger ribonucleoprotein (FMRP). Most individuals with FXS have an FMR1 allele with > 200 CGG repeats (full mutation) and hypermethylation of the CpG island proximal to the repeats, which silences the gene's promoter. Some individuals have mosaicism in the size of the CGG repeats or in hypermethylation of the CpG island, both produce some FMRP and give rise to milder cognitive and behavioral deficits than in non-mosaic individuals with FXS. As in several monogenic disorders, modifier genes influence the penetrance of FMR1 mutations and FXS's variable expressivity by regulating the pathophysiological mechanisms related to the syndrome's behavioral features. Although there is no cure for FXS, prenatal molecular diagnostic testing is recommended to facilitate early diagnosis. Pharmacologic agents can reduce some behavioral features of FXS, and researchers are investigating whether gene editing can be used to demethylate the FMR1 promoter region to improve patient outcomes. Moreover, clustered regularly interspaced palindromic repeats (CRISPR)/Cas9 and developed nuclease defective Cas9 (dCas9) strategies have promised options of genome editing in gain-of-function mutations to rewrite new genetic information into a specified DNA site, are also being studied.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transtorno do Espectro Autista / Síndrome do Cromossomo X Frágil Tipo de estudo: Risk_factors_studies / Screening_studies Limite: Female / Humans / Male Idioma: En Revista: Hum Genomics Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transtorno do Espectro Autista / Síndrome do Cromossomo X Frágil Tipo de estudo: Risk_factors_studies / Screening_studies Limite: Female / Humans / Male Idioma: En Revista: Hum Genomics Ano de publicação: 2023 Tipo de documento: Article